[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:constipation":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,42,66,95,116,142,170,188,212,232,258,281,320,347,383,403,431,456,481,507,530,553,573,595,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100350376","understanding-mechanisms-of-normal-and-disordered-defecation-100350376",false,"NCT03842007","Understanding Mechanisms of Normal and Disordered Defecation","Inclusion Criteria\n\n* Male and female volunteers aged 18-80 years.\n* Able to provide written informed consent before participating in the study.\n* Able to communicate adequately with the investigator and to comply with the requirements for the entire study.\n* Individuals with chronic constipation for 1 year, with 2 or more of the following symptoms for 3 months or longer: \\\u003C3 bowel motions\u002Fweek, straining ≥ 25% of time, hard or lumpy stools ≥ 25% of time, anal digitation ≥ 25% of time, incomplete evacuation ≥ 25% of time, feeling of anorectal blockage ≥ 25% of time.\n* Able to provide written informed consent before participating in the study.\n* Able to communicate adequately with the investigator and to comply with the requirements for the entire study.\n\nExclusion Criteria\n\n* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and\u002For pose safety concerns.\n* Current symptoms of a functional gastrointestinal disorder assessed by questionnaire.\n* Putative risk factors for pelvic floor trauma: i.e. six or more vaginal deliveries, birthweight \\>4500gms (macrosomia), or known 3rd or 4th degree perineal tear.\n* Medications that are likely to alter gastrointestinal motility: e.g., opiates and anticholinergic medications; a stable dose of thyroxine and low doses of tricyclic agents (e.g., up to amitriptyline (50 mg daily).\n* Active rectal inflammation, cancer; perianal sepsis; history of pelvic radiation, rectosigmoid surgery or inflammatory bowel disease.\\*\n* Anxiety or depression as assessed by the Hospital Anxiety and Depression Questionnaire.\n* Pregnant women, prisoners and institutionalized individuals.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","Researchers are trying to better understand why constipation occurs and improve the tests for diagnosing these conditions.",[28],"Constipation","RECRUITING","2026-08-19",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":33},"2019-01-29",{"date":37,"type":22},"2029-06",{"name":39,"class":40},"Mayo Clinic","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100647826","radicle-gi-healthtm-vnb-a-study-assessing-the-impact-of-health-and-wellness-products-on-constipation-and-related-health-outcomes-100647826","NCT07713810","Radicle GI HealthTM VNB: A Study Assessing the Impact of Health and Wellness Products on Constipation and Related Health Outcomes","Radicle GI HealthTM VNB: A Randomized, Double-Blind, Placebo- Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Constipation and Related Health Outcomes","3.1 Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\n3.2 Exclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and\u002For similar product(s) to the active study product(s) that may limit the effects of the study products and\u002For pose a safety risk\n\n  * Reports taking any product for acute constipation\n  * Reports taking any medications containing levodopa\n* Lack of reliable daily access to the internet","21 Years","105 Years",{"count":52,"type":22},550,[25],"Radicle GI HealthTM VNB: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on constipation and related health outcomes",[28],"2026-08-18",{"date":58,"type":33},"2026-08-20",{"date":60,"type":33},"2026-07-30",{"date":62,"type":22},"2027-07-16",{"name":64,"class":65},"Radicle Science","INDUSTRY",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":72,"maxAge":18,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100502365","phase-4-evaluation-of-fecal-microbiome-changes-after-antegrade-continence-enema-placement-and-initiation-of-bowel-flush-regimen-100502365","NCT05821309","Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen","Inclusion Criteria:\n\n* Recalcitrant chronic functional constipation necessitating a MACE appendicostomy or cecostomy for treatment at Riley Hospital for Children\n* Intact colonic motility as evidenced by CMS studies\n\nExclusion Criteria\n\n* Underlying anatomic or pathologic etiology for constipation\n* History of prior gastrointestinal surgery (excluding placement of G or GJ tubes)\n* Underlying severe GI disease unrelated to the patient's chronic constipation\n* Use within the past month of consent of probiotic supplements, prebiotic supplements or antibiotics","2 Years",{"count":74,"type":22},65,[76],"PHASE4","This study will evaluate changes in the fecal microbiome in constipated pediatric patients before and after antegrade continence enema placement and initiation of antegrade enema flushes. Subjects will have their microbiome sequenced prior to placement by obtaining a fecal sample. Pre-antegrade continence enema placement results will be compared to fecal samples obtained at 0, 4, 8 months after placement of the antegrade continence enema and initiation of miralax or golytely flushes to look for changes in bacterial diversity.",[28],[80,81,82,83,84,85],"Fecal microbiome","Malone Antegrade Continence Enema (MACE)","Miralax","PEG 3350","Antegrade Continence Enema","Chronic Constipation","2026-08-17",{"date":56,"type":33},{"date":89,"type":33},"2023-06-08",{"date":91,"type":22},"2027-07",{"name":93,"class":40},"Indiana University",2,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":41},"100651834","probiotics-improve-constipation-100651834","NCT07765004","Probiotics Improve Constipation","Safety and Efficacy of Probiotics for Constipation Relief in Adults: A Randonmized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 65 years (inclusive).\n* Diagnosed with constipation, defined as fewer than 3 spontaneous bowel movements per week and\u002For Bristol Stool Form Scale types 1 or 2.\n* Willing and able to comply with the study protocol and complete all required assessments.\n* Provide written informed consent prior to any study-related procedures.\n* Male and female participants of childbearing potential must agree to use effective contraception voluntarily from 14 days prior to screening until 6 months after the end of the trial. Female participants of non-childbearing potential (e.g., post-menopausal or surgically sterile) are exempt from this requirement.\n\nExclusion Criteria:\n\n* Use of products with functions similar to the investigational product within a short period prior to screening that may interfere with the evaluation of study outcomes.\n* Intention to change dietary habits significantly during the study period.\n* Severe allergies or immunodeficiency.\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial.\n* Severe diseases of vital organs (including cardiovascular, pulmonary, hepatic, or renal disease), metabolic diseases (e.g., diabetes, thyroid disorders), malignancy, or severe immune system disorders.\n* Use of antibiotics within the past 30 days.\n* Severe psychological or psychiatric disorders.\n* Poor compliance (e.g., failure to take the test product as instructed or failure to attend scheduled follow-up visits) that would preclude a valid assessment of efficacy.\n* Organic constipation (e.g., caused by structural or pathological conditions).\n* Irritable bowel syndrome with constipation (IBS-C).\n* History of surgical procedures within 30 days prior to screening that may have caused or contributed to constipation symptoms.\n* Intake of probiotic or prebiotic supplements within one month prior to the start of the study.\n* Any other condition that, in the investigator's opinion, would make the participant unsuitable for participation in the study.","65 Years",{"count":104,"type":22},76,[25],"This study is a randomized, double-blind, placebo-controlled trial in which adult subjects with constipation are randomly assigned to either a probiotic group or a placebo group for an 8-week intervention. Through blood and fecal sample analyses combined with multidimensional questionnaire assessments, the study aims to systematically evaluate the efficacy of probiotics in improving gastrointestinal function, immune status, and mental health in patients with constipation.",[28],"2026-08-13",{"date":86,"type":33},{"date":111,"type":22},"2026-08-07",{"date":113,"type":22},"2026-12-20",{"name":115,"class":65},"Wecare Probiotics Co., Ltd.",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100634906","phase-2-a-study-of-brenipatide-ly3537031-in-participants-with-irritable-bowel-syndrome-constipation-ibs-c-100634906","NCT07545772","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C","RENEW-IBS-C","Inclusion Criteria:\n\n* Meets Rome IV criteria for irritable bowel syndrome-constipation (IBS-C) including having more than 25% bowel movements with Bristol Stool Form Scale (BSFS) Types 1 or 2 and less than 25% of bowel movements with BSFS Types 6 or 7\n* Based on the daily eDiary collection during the screening period:\n\n  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization\n\nExclusion Criteria:\n\n* Have a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea, mixed IBS, or unclassified IBS by the Rome IV criteria\n* Have a history of inflammatory or immune-mediated gastrointestinal disorders\n* Have a known clinically significant gastric emptying abnormality","75 Years",{"count":126,"type":22},342,[128],"PHASE2","The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.\n\nThe study will last approximately 35 weeks.",[131,28],"Irritable Bowel Syndrome","2026-08-05",{"date":134,"type":33},"2026-08-06",{"date":136,"type":33},"2026-04-29",{"date":138,"type":22},"2027-09",{"name":140,"class":65},"Eli Lilly and Company",70,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":41},"100648163","study-of-transanal-irrigation-vs-standard-care-for-constipation-gut-microbiota-and-motor-disorders-in-parkinsons-disease-100648163","NCT07716553","Study of Transanal Irrigation vs Standard Care for Constipation, Gut Microbiota, and Motor Disorders in Parkinson's Disease","Trial Comparing the Efficacy of Transanal Irrigation Versus Standard Bowel Care in Patients With Parkinson's Disease and Severe Constipation. Impact on Gut Microbiome and Motor Disorders. TAI-PD Study.","TAI-PD","Inclusion Criteria:\n\n* For inclusion in the study, subjects must fulfil all of the following criteria:\n\n  1. Provision of informed consent.\n  2. Female or male aged 18 years or above.\n  3. Established diagnosis of PD according to MDS criteria\n  4. Patients with bowel symptoms post-dating and related to a diagnosis of PD.\n  5. PD patients suffering from constipation defined by Cleveland Clinic (Wexner) constipation score ≥10 confirmed at Baseline.\n  6. Only TAI treatment naïve patient (not having previously used any particular TAI system).\n  7. Judged eligible for TAI as per standardized treatment pathway .\n  8. Able to read, write and understand information given to them regarding the study.\n\nExclusion Criteria\n\nAny of the following is regarded as a criterion for exclusion from the study:\n\n* Any confirmed or suspected diagnosis of anal or colorectal stenosis, active inflammatory bowel disease, acute diverticulitis, severe diverticulosis, colorectal cancer, ischemic colitis, history of life-threatening autonomic dysreflexia, bleeding disorders, unspecified peri-anal conditions.\n* Other significant neurological diseases (defined as all neurological diseases except for minor functional neurological syndromes or non-PD related neuro complications).\n* Opioid consumption ≤24 hours prior enrolment.\n* Taking probiotics in the past 30 days.\n* Antibiotic therapy in the past 3 weeks.\n* Performed endoscopic polypectomy within 4 weeks prior enrolment.\n* Ongoing, confirmed pregnancy or lactation.\n* Any neuromodulation that can affect the pelvic organ function.\n* Current treatment of prokinetics.\n* Any other condition, as judged by the investigator, might make follow-up or investigations inappropriate.\n\nExclusion Criteria:\n\n\\-",{"count":151,"type":22},200,[25],"Constipation is one of the most common and disabling non-motor symptoms of Parkinson's disease (PD), often resulting in reduced quality of life and increased healthcare burden. Standard bowel care (SBC), including dietary modifications, fluid intake, physical activity, and laxative therapy, may not provide adequate symptom control in patients with severe constipation.\n\nThe purpose of this study is to evaluate whether transanal irrigation (TAI) using the Qufora Flow device is more effective than SBC in improving bowel function in patients with PD and severe constipation. In addition to bowel symptom improvement, the study will investigate the potential effects of TAI on gut microbiota composition, motor and non-motor symptoms of PD, treatment adherence, and safety.\n\nParticipants will be randomly assigned to receive either TAI or SBC and will be followed for 24 months. Clinical assessments, patient-reported outcome measures, and stool samples will be collected throughout the study to evaluate treatment effectiveness and to explore the relationship between bowel management, gut microbiota, and Parkinson's disease progression.",[155,28],"Parkinson Disease",[157,28,158,159,160],"Parkinson","Transanal Irrigation","Gut Micriobiome","TAI","NOT_YET_RECRUITING","2026-07-28",{"date":60,"type":33},{"date":165,"type":22},"2026-09-30",{"date":167,"type":22},"2029-09-30",{"name":169,"class":40},"University Hospital of Ferrara",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":41},"100633651","adults-with-constipation-100633651","NCT07529457","Adults With Constipation","To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Men and women aged between 18 and 65 years;\n2. Participants presenting with constipation, characterized by \\\u003C3 spontaneous bowel movements per week or BSFS stool types 1-2;\n3. Capable of following the study protocol and completing all required assessments; Individuals who have voluntarily signed the informed consent form;\n4. No plans for pregnancy from at least 14 days prior to screening through 6 months after the study, with agreement to use reliable contraception methods.\n\nExclusion Criteria:\n\n1. Intake of similar functional products within a short period prior to enrollment that could influence study results;\n2. Participants who significantly alter their habitual diet during the trial;\n3. Individuals with severe allergic conditions or impaired immune function;\n4. Women who are pregnant, lactating, or intending to conceive;\n5. Patients with serious underlying diseases affecting major organs or metabolic systems;\n6. Antibiotic treatment within 2 weeks before enrollment;\n7. Individuals with severe mental or psychological disorders;\n8. Non-compliance with study requirements, including improper intake or missed follow-ups;\n9. Other subjects considered inappropriate for participation by the investigator.",{"count":141,"type":22},[25],"This randomized, double-blind, placebo-controlled trial will assess the clinical effects of Akk09 in adults with functional constipation. Participants will receive Akk09 or placebo for 8 weeks. The study will evaluate changes in bowel habits and symptom burden, as well as alterations in host inflammatory status, immune modulation, microbial ecosystem dynamics, neuroendocrine signaling related to the gut-brain axis, and systemic metabolic responses, to characterize the overall physiological impact of Akk09 supplementation.",[28],"2026-07-23",{"date":183,"type":33},"2026-07-24",{"date":183,"type":22},{"date":186,"type":22},"2027-05-20",{"name":115,"class":65},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":41},"100642940","phase-1-research-on-the-efficacy-and-mechanism-of-shouhui-tongbian-capsules-in-treating-postoperative-constipation-of-benign-anal-and-rectal-diseases-based-on-gut-microbiota-analysis-100642940","NCT07648394","Research on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis","Inclusion Criteria:\n\nSurgical indication for a benign anorectal disease, including hemorrhoids or anal fistula Diagnosis of postoperative constipation after benign anorectal surgery Postoperative constipation symptoms such as difficulty defecating, reduced bowel movement frequency, hard or lumpy stools, incomplete evacuation, anorectal obstruction, or abdominal distension Ability to tolerate the planned anorectal surgical procedure without related contraindications Consciousness and ability to cooperate with treatment, follow-up, and questionnaire assessments Written informed consent provided by the participant or legally authorized representative Age 18 to 75 years, inclusive\n\nExclusion Criteria:\n\nSevere systemic disease, including serious psychiatric or immune disorders Severe infection Malignant tumor Severe organic disease of a major organ, including the heart, liver, or kidneys Pregnancy Breastfeeding Postpartum period Coagulation dysfunction Other anorectal disease that may affect outcome assessment Known allergy to either study treatment or any treatment component Any other condition considered by the investigators to make participation unsuitable",{"count":195,"type":22},120,[197,128],"PHASE1","The goal of this clinical trial is to evaluate whether Shouhui Tongbian Capsule can improve postoperative constipation in adults aged 18 to 75 years after surgery for benign anorectal diseases, including hemorrhoids and anal fistula. The clinical trial will also evaluate the safety of Shouhui Tongbian Capsule and explore associations between treatment effects and changes in gut microbiota, metabolic profiles, and inflammatory indicators.\n\nThe main questions are:\n\nDoes Shouhui Tongbian Capsule improve constipation symptoms after benign anorectal surgery? Does Shouhui Tongbian Capsule reduce postoperative and defecation-related pain? Does Shouhui Tongbian Capsule improve quality of life and anorectal function? What adverse events occur during treatment? Are clinical improvements associated with changes in gut microbiota, metabolic profiles, or inflammatory indicators?\n\nResearchers will compare Shouhui Tongbian Capsule with lactulose to evaluate differences in efficacy and safety for postoperative constipation.\n\nParticipants will:\n\nReceive either Shouhui Tongbian Capsule three times daily or lactulose once daily for 14 days Complete assessments of constipation symptoms, pain, quality of life, and anorectal function Provide stool and blood samples before treatment and on Day 14 Attend assessments during treatment and approximately 1 month after surgery Report adverse events and other medical problems during participation",[200,201,202,28],"Intestinal Flora","Anorectal Diseases","Surgery","2026-07-21",{"date":205,"type":33},"2026-07-22",{"date":207,"type":22},"2026-08-01",{"date":209,"type":22},"2027-06-30",{"name":211,"class":40},"China-Japan Friendship Hospital",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100648499","phase-2-butyrate-yogurt-for-cancer-constipation-100648499","NCT07723729","Butyrate Yogurt for Cancer Constipation","A Phase II Study on the Efficacy and Safety of Butyrate-Containing Short-Chain Fatty Acid Yogurt in Constipation in Patients With Gastrointestinal Malignancies","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically confirmed diagnosis of gastrointestinal malignancy.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n4. Confirmed \\\u003C 3 spontaneous bowel movements (CSBM) per week during the 1-week baseline period, accompanied by constipation-related symptoms (e.g., straining, hard\u002Flumpy stools, sensation of incomplete evacuation, etc.).\n5. Anticancer treatment regimen is expected to remain relatively stable during the study period.\n6. Willing and able to provide written informed consent and complete electronic diary entries.\n\nExclusion Criteria:\n\n1. Mechanical intestinal obstruction, active inflammatory bowel disease, severe rectal stricture, or acute abdomen.\n2. Absolute neutrophil count (ANC) \\\u003C 1.0 × 10⁹\u002FL or active infection.\n3. New initiation or major dose adjustment of prosecretory or prokinetic agents within the past 2 weeks.\n4. Allergy or hypersensitivity to dairy products or any component of the butyrate-containing yogurt formulation.\n5. Deemed unsuitable for enrollment by the investigator (e.g., poor compliance, cognitive impairment, or other conditions that may interfere with study participation).",{"count":220,"type":22},30,[128],"Constipation is a common yet underrecognized supportive care issue in cancer patients. Its consequences extend beyond physical discomfort to include impaired quality of life, reduced opioid adherence leading to inadequate analgesia, and increased risks of fecal impaction, emergency visits, and hospitalization. Current management strategies-including laxatives, stool softeners, prokinetics, and PAMORAs-remain suboptimal due to limited effects on gut dysbiosis, mucosal barrier dysfunction, and chronic inflammation, as well as issues related to polypharmacy, variable efficacy, and long-term tolerability. Hence, there is a clear need for novel, well-tolerated, long-term interventions with nutritional benefits that target the gut microbiota-mucosal barrier-motility axis.\n\nShort-chain fatty acids (SCFAs), particularly butyrate, are key microbial metabolites that may improve constipation through multiple mechanisms: enhancing intestinal motility via enteric nervous system regulation, reinforcing mucosal barrier integrity and mitigating low-grade inflammation, and restoring gut microbial-metabolite homeostasis. Butyrate supplementation therefore holds mechanistic promise for cancer-related constipation.\n\nThe \"Small Blue Can High Dietary Fiber Butyrate SCFA Yogurt\" (Blueglass) is designed with a \"probiotics + prebiotics + acids\" synergistic fermentation platform, delivering ≥70 mg\u002F100 g butyrate combined with high dietary fiber. Compared with conventional laxatives or single-agent butyrate, this yogurt-based formulation offers potential advantages in patient acceptability, long-term adherence, dual exogenous and endogenous SCFA support, and multi-target action on motility, microbiome, and barrier function, making it a promising candidate for supportive care in this population.",[28,224],"Gastrointestinal Cancer","2026-07-20",{"date":181,"type":33},{"date":207,"type":22},{"date":229,"type":22},"2027-12-30",{"name":231,"class":40},"Tianjin Medical University Cancer Institute and Hospital",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":41},"100647274","balloon-inflation-in-biofeedback-100647274","NCT07705542","Balloon Inflation in Biofeedback","Analysing the Impact of Balloon Inflated vs Balloon Deflated Push Manoeuvres in Chronically Constipated Patients During Biofeedback Therapy","Inclusion Criteria:\n\n* dyssynergia, constipation, obstructive defecation\n\nExclusion Criteria:\n\n* Patients with anorectal inflammation due to conditions such as solitary rectal ulcer syndrome\n* Patients with significantly altered anorectal anatomy due to abnormalities such as large rectocele, rectal prolapse or intussusception\n* History of major anorectal surgery\n* Unable to be investigated with HR-ARM due to contraindications such as recent anorectal surgery (\\\u003C6 weeks), active anorectal infections, severe anal pain or fissures(?), thrombosed haemorrhoids, or inability to tolerate anorectal catheters\n* Patients with pre-existing co-morbid inflammatory gastrointestinal conditions, including\n* Coeliac and Crohn's disease",{"count":240,"type":22},10,[25],"Chronic constipation, particularly due to dyssynergic defecation, is common and impacts quality of life. Biofeedback therapy (BFT) is the most effective conservative treatment, teaching patients to coordinate abdominal and anal muscles during defecation. In standard practice, the rectal balloon used in high-resolution anorectal manometry (HRAM) and biofeedback is left deflated, though some centres inflate it to simulate a more natural urge to defecate.\n\nHowever, the efficacy of this modification has not been validated. This study aims to determine whether performing BFT with the balloon inflated to a patient's defecatory desire volume enhances physiological coordination and patient understanding compared to the standard deflated approach.",[28,85,244,245],"Dyssynergia","Anismus",[247],"biofeedback","2026-07-13",{"date":250,"type":33},"2026-07-15",{"date":252,"type":33},"2026-05-13",{"date":254,"type":22},"2026-07",{"name":256,"class":257},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":41},"100579721","phase-2-a-study-of-microbiome-transplantation-for-the-treatment-of-constipation-andor-significant-bloating-in-patients-with-systemic-sclerosis-100579721","NCT06827977","A Study of Microbiome Transplantation for the Treatment of Constipation and\u002For Significant Bloating in Patients With Systemic Sclerosis","Inclusion Criteria:\n\n* Are seen in the UT Houston Scleroderma Center (UTHSC)\n* Meet 2013 American college of rheumatology (ACR)\u002FEuropean league against rheumatism (EULAR) criteria or CREST criteria for SSc\n* Meet Rome IV criteria for constipation and\u002For significant bloating\n* Subject willing to sign an informed consent form\n* Subject deemed likely to survive for ≥ 1 year after enrollment\n* Able to follow study procedure and follow-up\n* Sexually active male and female subjects of childbearing potential must agree to use an effective method of birth control during the treatment and follow-up period\n* Female subjects of childbearing potential must have a negative pregnancy test in the 72 hours before the procedure\n* Subjects who agree to adhere to a stable diet for at least 4 weeks before joining the study and throughout the study\n* Subjects must have an attending physician who will provide non-transplant care for the subject\n\nExclusion Criteria:\n\n* Subjects with constipation and\u002For significant bloating from causes not attributed to SSc as determined by the treating physician (e.g., inflammatory bowel disease, medication, significant diabetes, or hypothyroidism, etc.)\n* Subjects unwilling to stop taking probiotic supplements during the duration of the study\n* Subjects that have post-total or hemicolectomy or the presence of a colostomy\n* Subjects unable to tolerate microbiome transplant via enema for any reason or swallow capsules\n* Subjects requiring systemic antibiotic therapy 4 weeks before the study\n* If subjects are on immunosuppression, the immunosuppression dose should be stable for at least 4 weeks before study enrollment",{"count":265,"type":22},21,[128],"The purpose of this study is to characterize the intestinal flora in subjects with systemic sclerosis-related constipation and\u002For significant bloating and to determine safety and trends in improvements in the diversity of colonic microbiome and patient symptoms following the administration of either frozen or lyophilized PRIM-DJ2727 microbiota.",[28,269],"Bloating",[271],"Systemic Sclerosis","2026-07-05",{"date":274,"type":33},"2026-07-08",{"date":276,"type":33},"2025-03-03",{"date":278,"type":22},"2028-06-30",{"name":280,"class":40},"The University of Texas Health Science Center, Houston",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":291,"studyType":292,"phases":4,"briefSummary":293,"conditions":294,"keywords":298,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":41},"100643888","glp-1-receptor-agonists-and-early-proctologic-effects-in-morbid-obesity-100643888","NCT07668765","GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity","Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment","GLP-PROCT","Inclusion Criteria:\n\n* Age ≥18 years\n* Morbid obesity (BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities)\n* Newly prescribed GLP-1 receptor agonist therapy\n* Ability and willingness to provide written informed consent\n* Ability to attend 3-month follow-up visit\n\nExclusion Criteria:\n\n* Inflammatory bowel disease\n* Perianal Crohn's disease\n* History of anorectal malignancy\n* Previous pelvic radiotherapy\n* Anorectal surgery within the previous 3 months\n* Pregnancy\n* Neurogenic bowel dysfunction\n* Inability to comply with follow-up visits\n* Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment\n* Active anorectal infection or abscess",{"count":290,"type":22},100,"3 Months","OBSERVATIONAL","Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.",[295,201,296,28,297],"Morbid Obesity","Drug-Related Side Effects and Adverse Reactions","Diarrhea",[299,300,301,302,303,304,305,306,307,308,309,310],"GLP-1 receptor agonist","obesity","anorectal symptoms","hemorrhoids","anal fissure","constipation","semaglutide","tirzepatide","proctologic examination","bowel habits","anorectal disease","proctology","2026-06-23",{"date":313,"type":33},"2026-06-25",{"date":315,"type":22},"2026-08",{"date":317,"type":22},"2027-05",{"name":319,"class":40},"Gazi University",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":292,"phases":4,"briefSummary":328,"conditions":329,"keywords":332,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":41},"100641433","test-anxiety-on-bowel-health-and-constipation-in-students-100641433","NCT07654959","Test Anxiety on Bowel Health and Constipation in Students","The Effect of Test Anxiety on Bowel Health and Constipation in University Students","Inclusion Criteria:\n\n* Being an undergraduate student in the Department of Physiotherapy and Rehabilitation at Lokman Hekim University\n* Being in the final examination period during the data collection process\n* Having sufficient reading and comprehension skills to complete the questionnaires independently\n* Voluntarily agreeing to participate in the study after reading and signing the informed consent form\n\nExclusion Criteria:\n\n* Having inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, celiac disease, colorectal cancer, or a history of major gastrointestinal surgery\n* Having diagnosed irritable bowel syndrome or another organic gastrointestinal disease\n* Regular use of laxatives or medications that directly affect bowel movements, such as opioids\n* Having neurological diseases that may affect bowel function, such as multiple sclerosis, Parkinson's disease, or spinal cord injury\n* Having had an acute gastrointestinal infection within the last month",{"count":151,"type":22},"This observational cross-sectional study aims to examine the relationship between test anxiety, bowel health, and constipation in university students. The study will include undergraduate students aged 18 years and older who are studying in the Physiotherapy and Rehabilitation Department at Lokman Hekim University and who are in their final examination period.\n\nParticipants will complete self-report questionnaires during a single face-to-face assessment session. Constipation status will be evaluated using the Rome IV criteria, stool form will be assessed using the Bristol Stool Scale, constipation severity will be assessed using the Constipation Severity Instrument, and test anxiety level will be assessed using the Test Anxiety Inventory. Sociodemographic characteristics and bowel-related symptoms will also be recorded.\n\nThe study does not include any intervention or treatment. The findings are expected to help better understand whether test anxiety during examination periods is associated with bowel health problems and constipation in university students.",[330,331,28],"Anxiety","Bowel Habits",[333,334,335,336,337],"Test anxiety","Examination stress","Bowel health","Rome IV criteria","University students","2026-06-17",{"date":340,"type":33},"2026-06-22",{"date":342,"type":33},"2026-02-25",{"date":344,"type":22},"2027-02-25",{"name":346,"class":257},"Lokman Hekim University",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":354,"targetDuration":356,"studyType":292,"phases":4,"briefSummary":357,"conditions":358,"keywords":367,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":41},"100401388","indiana-university-gastrointestinal-motility-diagnosis-registry-100401388","NCT04506593","Indiana University Gastrointestinal Motility Diagnosis Registry","Gastrointestinal Motility Diagnosis Registry","Inclusion Criteria:\n\n1. Patients who presented to the GI outpatient clinics, in-patient consult service, and outpatient endoscopy centers within the Division of Gastroenterology and Hepatology\n2. Carries a diagnosis of GI motility disorder based on the diagnostic criteria listed in table\n\nExclusion Criteria:\n\n1\\. Coexisting medical conditions that may limiting participation in clinical research trial",{"count":355,"type":22},5000,"10 Years","Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders",[359,360,361,362,363,28,364,365,366],"Eosinophilic Esophagitis","Gastroesophageal Reflux Disease (GERD)","Gastroparesis","Functional Vomiting","Irritable Bowel Syndrome (IBS)","Chronic Intestinal Pseudo-obstruction","Fecal Incontinence","Small Intestinal Bacterial Overgrowth",[368,369,370,371,372,373,374,361],"Eosinophilic esophagitis","Chronic intestinal pseudo-obstruction","Small Bowel dysmotility","SIBO","Vomiting","Functional dyspepsia","Functional bloating","2026-06-15",{"date":377,"type":33},"2026-06-16",{"date":379,"type":33},"2014-11-01",{"date":381,"type":22},"2026-11",{"name":93,"class":40},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":41},"100628503","probiotic-improve-constipation-100628503","NCT07462481","Probiotic Improve Constipation","A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Probiotics in Relieving Constipation in Adults","Inclusion Criteria:\n\n(1) Age 18-65 years; (2) Constipated patients (less than 3 bowel movements per week and\u002For Bristol Scale type 1 and 2); (3) Able to complete the study according to the trial protocol; (4) Patients who have signed the informed consent form; (5) Study participants (including male study participants) have no plans to have children within 14 days prior to screening and within 6 months after the end of the trial and voluntarily use effective contraception.\n\n\\-\n\nExclusion Criteria:\n\n1. Those who have taken a substance with a similar function to the test subject in a short period of time, affecting their judgment of the results;\n2. Patients who changed their diet during the study;\n3. Patients with severe allergies and immunodeficiency;\n4. Pregnant, breastfeeding, or women planning to become pregnant;\n5. Those with severe diseases of vital organs such as the cardiovascular system, lungs, liver, and kidneys, diabetes, thyroid disease, severe metabolic diseases, malignant tumors, or severe immune system diseases;\n6. Those who have used antibiotics in the past two weeks;\n7. Those with severe psychological or mental illnesses;\n8. Those who did not consume the test sample as required or did not follow up on time, resulting in the inability to determine the efficacy;\n9. Other study participants deemed unsuitable by the researchers. -",{"count":391,"type":22},105,[25],"To evaluate the efficacy and safety of probiotic as a food supplement in regulating bowel habits in patients with chronic constipation, and to compare it with placebo.",[28],"2026-06-05",{"date":397,"type":33},"2026-06-09",{"date":399,"type":22},"2026-06-10",{"date":401,"type":22},"2027-08-01",{"name":115,"class":65},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":430},"100599945","a-study-of-herbal-supplements-in-cancer-survivors-with-constipation-100599945","NCT07091084","A Study of Herbal Supplements in Cancer Survivors With Constipation","Herbal Formula Ma-Zi-Ren-Wan (MZRW) on Bowel Movement Function and Gut Microbiome Among Cancer Survivors With Constipation: A Double-blinded Randomized Controlled Trial (RELIEVE)","Inclusion Criteria:\n\n* Age 18 years or greater;\n* A diagnosis of cancer with no restrictions placed on type of cancer or stage;\n* Completed surgery, chemotherapy, immunotherapy, and\u002For radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;\n* Karnofsky functional score of ≥ 60;\n* Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:\n\n  * Straining more than 25% of defecations.\n  * Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.\n  * Sensation of incomplete evacuation more than one-fourth (25%) of defecations.\n  * Sensation of anorectal obstruction\u002Fblockage more than one-fourth (25%) of defecations.\n  * Manual maneuvers to facilitate more than one-fourth (25%) of defecations.\n  * Fewer than three spontaneous bowel movements per week.\n  * Loose stools are rarely present without the use of laxatives.\n  * Insufficient criteria for irritable bowel syndrome.\n* Patient should be able to understand and complete all study assessments on their own\n* Patient should be able to understand and provide signed informed consent in English.\n\nTable 3. Rome IV criteria for functional constipation FUNCTIONAL CONSTIPATION Diagnostic criteria\\*\n\n1. Must include two or more of the following:\\*\\*\n2. Straining during more than ¼ (25%) of defecations\n3. Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations\n4. Sensation of incomplete evacuation more than ¼ (25%) of defecations\n5. Sensation of anorectal obstruction\u002Fblockage more than ¼ (25%) of defecations\n6. Fewer than three SBM per week\n7. Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)\n\n9\\. Loose stools are rarely present without the use of laxatives 9. Insufficient criteria for irritable bowel syndrome Note \\*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis\n\nExclusion Criteria:\n\n* Patients who have allergic history to herbs or Chinese medicine;\n* Clinically significant abnormal liver (2 times the ULN for ALT or AST) and kidney disfunction(eGFR below 59 mL\u002Fmin\u002F1.73m² ) from recent laboratory test recorded in the medical record (within 2 month);\n* Patients who have any signs of bowel obstruction, or have high risk of bowel obstruction assessed by their treating physician, including factors such as tumor invasion into abdominal organs, recent abdominal surgery, and prior abdominal radiation therapy;\n* Patients who are prescribed opioid antagonists including methylnaltrexone, naloxegol and naldemedine for opioid induced constipation and required not to stop the medication;\n* Women who are pregnant, lactating, or not practicing proper contraception by patient report.Patient's should follow proper contraception guidelines for at least 30 days following last dose of the study drug.",{"count":141,"type":22},[25],"The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with placebo, a pill that looks like MZRW and is given in the same way, but contains no medication. The researchers will also study the effect MZRW has on the gut microbiome. The gut microbiome is a diverse community of microorganisms living in the digestive system, essential for digestion and immune function.",[28,414,415],"Cancer","Functional Constipation",[304,417,418,419,420,421],"functional constipation","Ma-Zi-Ren-Wan","MZRW","25-076","Memorial Sloan Kettering Cancer Center","2026-05-20",{"date":424,"type":33},"2026-05-22",{"date":426,"type":33},"2025-07-15",{"date":428,"type":22},"2028-07-15",{"name":421,"class":40},7,{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":438,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":454,"locationsCount":41},"100627082","randomized-blinded-placebo-controlled-evaluation-of-bioamicus-complete-100627082","NCT07444008","Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete","A Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Dietary Supplement BioAmicus Complete (Oral Drops; a Mixture of 10 Strains of Lacto- and Bifidobacteria) in Managing Functional Gastrointestinal Disorders and Cutaneous Symptoms of Food Allergy in Infants During the First Months of Life","Inclusion Criteria:\n\n* The child's parents\u002Fguardians speak Russian, have been informed about the study's purpose, understand its essence, are aware of their rights, and have signed the informed consent form.\n* Diarrhea or constipation accompanied by colic and\u002For regurgitation (gastroesophageal reflux, GER).\n* Cutaneous manifestations of food allergy.\n* The child was born at term or preterm, but not before the 7th month of gestation.\n* Age at the time of parental informed consent: from 1 month to 4 months and 28 days.\n* The child is on breastfeeding, formula feeding, or mixed feeding.\n* The child has no other health conditions that would require a specialized diet.\n* The parents\u002Fguardians are able and willing to regularly complete the proposed observation diary form.\n\nExclusion Criteria:\n\n* The child has a congenital pathology or any other conditions\u002Fdiseases\u002Fclinical manifestations that may interfere with participation in the study.\n* Use of lactase supplements.\n* Use of other probiotic products, antibiotics, enteral antiseptics, antifungal, or antiprotozoal medications.\n* The child was born preterm (before the 7th month of gestation).","1 Month","5 Months",{"count":441,"type":22},140,[25],"This is a randomized, single-blind, placebo-controlled study to evaluate the efficacy of the dietary supplement BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria) in managing functional gastrointestinal disorders and cutaneous symptoms of food allergy in infants during the first months of life.\n\nThe aim of the study is to assess clinical effects of BioAmicus Complete drops on the symptoms of infantile colic, constipation, diarrhea, gastroesophageal reflux, atopic dermatitis\u002Feczema in full-term newborns during the first months of life.\n\nA prospective study comparing two treatment groups:\n\nGroup 1 (treatment group) - 70 infants. Group 2 (control group) - 70 infants, placebo. The study drug will be taken in 1 time per day within 25 days. Allowed symptomatic therapy includes defoamers (simethicone-based preparations), carminative preparations (dill water (fenhel)), etc.",[445,28,446,447],"Infantile Colics","Infantile Diarrhea","Atopic Dermatitis","2026-05-06",{"date":450,"type":33},"2026-05-11",{"date":452,"type":33},"2026-03-16",{"date":60,"type":22},{"name":455,"class":65},"NovoNatum Ltd",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":41},"100599369","efficacy-of-lcs-fermented-milk-on-constipation-related-symptoms-in-filipino-adults-100599369","NCT07083596","Efficacy of LcS-Fermented Milk on Constipation-Related Symptoms in Filipino Adults","The Efficacy of Fermented Milk Drink With Lacticaseibacillus Paracasei Strain Shirota (LcS) on Relieving Constipation-Related Symptoms of Filipino Adults","Inclusion Criteria:\n\n* Filipino adult male or female aged 18 to 59 years old\n* Apparently healthy adults with constipation-related symptoms of hard to lumpy stools (Bristol Stool Form Scale 1-2) in 25% or more of defecations in a week\n* With cold storage at home\n\nExclusion Criteria:\n\n1. Habitual intake of food items containing probiotics and prebiotics as food supplements (previous 3 months, at least three times per week)\n2. Constipation due to organic or neurologic origin\n3. High fiber intake (\\>30 g\u002Fday)\n4. Pregnant or lactating\n5. Allergy to dairy products and\u002For lactose intolerance\n6. Use of laxatives, anticholinergics and medications for constipation or diarrhea within the past three months\n7. Use of antibiotics within the past two weeks\n8. Presence of chronic diseases such as diabetes mellitus and its complications, cardiovascular diseases, kidney problems\n9. GI condition that may interfere with the evaluation of the outcome such as hemorrhoids, intestinal obstruction and inflammatory bowel diseases\n10. Recent history of any gastrointestinal surgery\n11. Have pre-existing medical conditions like hypo- or hyperthyroidism and congenital abnormalities\n12. Participation in another study with test product two months prior the study","59 Years",{"count":5,"type":22},[25],"The primary purpose of this study is to investigate whether the consumption of a probiotic drink (with Lacticaseibacillus paracasei strain Shirota (LcS)) relieves constipation-related symptoms of Filipino adults, specifically its effect on stool consistency, frequency, and duration, and on gastrointestinal discomfort.",[28,468],"Gastrointestinal Discomfort",[470,471,304],"probiotic","Lacticaseibacillus paracasei strain Shirota","2026-04-27",{"date":474,"type":33},"2026-05-04",{"date":476,"type":22},"2026-04-22",{"date":478,"type":22},"2026-10",{"name":480,"class":40},"University of Santo Tomas",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":492,"conditions":493,"keywords":496,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":41},"100633097","phase-3-rifaximin-treatment-in-bloating-predominant-functional-bowel-disorders-100633097","NCT07522255","Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders","The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Rome IV diagnosis of irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension.\n* Bothersome bloating with baseline severity of at least 3 on a 7-point Likert scale after adequate constipation treatment, defined as stool frequency from at least 3 times\u002Fweek to 3 times\u002Fday and Bristol Stool Form Scale type 3-5.\n* Colonoscopy, CT colonography, or barium enema performed if clinically indicated as part of standard evaluation for bowel symptoms.\n\nExclusion Criteria:\n\n* History of major gastrointestinal surgery, except appendectomy or laparoscopic cholecystectomy.\n* Inflammatory bowel disease or other inflammatory gastrointestinal conditions.\n* Current use of, or inability to discontinue, medications that may affect intestinal microbiota or gas measurements, including antibiotics, proton pump inhibitors, probiotics, lactulose, NSAIDs, or metformin.\n* Current use of, or inability to discontinue, medications that may affect bloating symptoms, including simethicone, simethicone-containing antispasmodics, or antidiarrheal medications.\n* Underlying conditions known to affect intestinal microbiota composition, including cirrhosis, uncontrolled diabetes mellitus, end-stage renal disease, obesity, malignancy, or psychiatric disorders.\n* Opioid-induced constipation.\n* Known allergy to rifaximin.",{"count":489,"type":22},78,[491],"PHASE3","This randomized, double-blind, placebo-controlled trial will evaluate whether a 14-day course of rifaximin improves bloating in adult patients with Rome IV functional bowel disorders in whom bloating is the predominant symptom. Eligible participants with irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension and bothersome bloating despite adequate bowel movement management will be assigned in a 1:1 ratio to rifaximin 550 mg three times daily or matching placebo for 2 weeks. The primary endpoint is the proportion of participants with bloating response, defined as at least a 1-point reduction from baseline in a 7-point Likert bloating score at the end of treatment.",[269,494,495,131,28],"Rifaximin","Functional Bowel Disorder",[494,269,497],"Functional bowel disorder","2026-04-03",{"date":500,"type":33},"2026-04-13",{"date":502,"type":22},"2026-04",{"date":504,"type":22},"2027-12",{"name":506,"class":40},"Mahidol University",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":515,"targetDuration":4,"studyType":292,"phases":4,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100629149","preoperative-fish-oil-pn-and-prognosis-after-constipation-surgery-100629149","NCT07470892","Preoperative Fish Oil PN and Prognosis After Constipation Surgery","Impact of Preoperative Fish Oil-Containing Parenteral Nutrition on Prognosis in Patients Undergoing Surgery for Constipation: A Prospective, Multicenter, Real-World Study","FOCP","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Meets diagnostic criteria for slow-transit constipation (STC) or megacolon and is scheduled for elective colon surgery.\n3. Nutritional Risk Screening 2002 (NRS2002) score \\>=3.\n4. Receives fish oil-containing parenteral nutrition (PN) for \\>=3 days preoperatively or initiates PN for the first time postoperatively (according to the study cohort definition).\n5. Voluntarily participates in the study and provides signed informed consent.\n\nExclusion Criteria:\n\n1. Mental disorders or other conditions that prevent cooperation with treatment or follow-up.\n2. Pregnant or breastfeeding women, women planning pregnancy \u002F in a pre-pregnancy state, or women with a clear intention to become pregnant during the perioperative period or follow-up.\n3. Contraindications to surgery or parenteral nutrition.\n4. Concurrent enrollment in another study.\n5. No baseline data available before initiation of nutritional support treatment.\n6. Any other condition judged by the investigator to make the participant unsuitable for this study.",{"count":516,"type":22},306,"This is a prospective, multicenter, real-world observational study to evaluate the impact of perioperative parenteral nutrition (PN) with fish oil-containing lipid emulsion on outcomes in adult patients with constipation undergoing elective colon surgery.\n\nThe study will compare two clinical nutrition strategies: (1) PN with fish oil-containing lipid emulsion started before surgery and continued after surgery, and (2) PN with fish oil-containing lipid emulsion started only after surgery. Eligible participants are adults (18-75 years) with slow-transit constipation (STC) or megacolon who are scheduled for elective colon surgery and have nutritional risk (NRS2002 score \\>=3).\n\nThe primary objective is to compare the incidence of postoperative complications between these two PN timing strategies. Secondary objectives include comparison of perioperative nutritional status, postoperative inflammatory status, prognosis, and safety outcomes.\n\nThis study will collect and analyze clinical data, laboratory indicators, perioperative recovery outcomes, follow-up assessments, and safety information in routine clinical practice. Outcomes include postoperative complication rates, changes in nutritional and inflammatory markers, bowel function recovery, length of hospital stay, constipation-related symptoms, quality of life, and adverse events. No experimental intervention will be assigned as part of this observational study.\n\nThe planned sample size is 306 participants. The findings may help optimize perioperative nutritional support strategies for patients with constipation undergoing surgery.",[28,519,520],"Slow Transit Constipation","Megacolon","2026-03-10",{"date":523,"type":33},"2026-03-13",{"date":525,"type":22},"2026-03",{"date":527,"type":22},"2029-09",{"name":529,"class":40},"Qianfoshan Hospital",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":537,"minAge":18,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":540,"briefSummary":541,"conditions":542,"keywords":543,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":551,"locationsCount":41},"100541894","optimization-of-postoperative-bowel-habits-100541894","NCT06335797","Optimization of Postoperative Bowel Habits","Optimization of Postoperative Bowel Habits Following Pelvic Reconstructive Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women ages 18 and older scheduled to undergo vaginal pelvic organ prolapse repair\n\nExclusion Criteria:\n\n* Women younger than 18 years old\n* Those unable to provide consent\n* Preexisting chronic laxative use\n* Conditions that could affect bowel function including, inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, rectovaginal fistula; concurrent bowel surgery; intraoperative bowel injury","FEMALE",{"count":539,"type":22},88,[25],"Project is a trial, in which women undergoing vaginal surgery for pelvic organ prolapse will be randomized 1:1 to a postoperative bowel regimen of either oral senna or rectal bisacodyl suppository.",[28],[331,544,545],"Pelvic Surgery","Laxatives",{"date":547,"type":33},"2026-02-27",{"date":549,"type":33},"2024-10-16",{"date":317,"type":22},{"name":552,"class":40},"Wake Forest University Health Sciences",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":41},"100485641","phase-2-pyridostigmine-for-the-treatment-of-constipation-in-parkinson-disease-100485641","NCT05603715","Pyridostigmine for the Treatment of Constipation in Parkinson Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Be able to provide signed informed consent\n3. Stated ability and willingness to comply with all study procedures\n4. Able to take oral medications\n5. Females of reproductive potential who are sexually active must be willing to use two of the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (female condom, diaphragm, cervical cap with\u002Fwithout spermicide), hormonal contraception, or intrauterine device; OR one of the previously mentioned methods AND partner must use barrier contraception (male condom with\u002Fwithout spermicide)\n6. Males of reproductive potential who are sexually active must be willing to use the following highly effective methods of contraception for the duration of study participation and for an additional 28 days after the end of study drug administration: barrier contraception (male condom with\u002Fwithout spermicide) AND partner must be postmenopausal, use hormonal contraception, have an intrauterine device, or use barrier contraception (female condom, diaphragm, cervical cap with\u002Fwithout spermicide)\n7. Meet United Kingdom Parkinson's Disease Society Brain Bank Criteria:\n\n   A. Diagnosis of a parkinsonism:\n   * Bradykinesia, plus at least one of the following:\n   * Muscular rigidity\n   * 4-6 Hz resting tremor\n   * Postural stability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction\n\n   B. At least three supportive criteria:\n   * Unilateral onset of symptoms\n   * Rest tremor\n   * Progressive symptoms\n   * Persistent asymmetry affecting the side of onset most\n   * Excellent response to levodopa\n   * Severe levodopa-induced chorea\n   * Levodopa response for five years or more\n   * Clinical course of 10 years or more\n8. Fulfill the ROME IV Criteria for Functional Constipation, with a specific requirement that the patient must have three or fewer defecations per week (criterion Ai):\n\n   * Must include two or more of the following:\n\n     i. Three or fewer defecations per week ii. Straining during \\> 25% of defecations iii. Lumpy or hard stools in \\> 25% of defecations iv. Sensation of incomplete evacuation for \\> 25% of defecations v. Sensation of anorectal obstruction\u002Fblockage for \\> 25% of defecations vi. Manual maneuvers to facilitate \\> 25% of defecations\n   * Loose stools are rarely present without the use of laxatives\n   * Insufficient criteria for irritable bowel syndrome\n   * Criteria 1-3 must be fulfilled for at least three months with onset of symptoms at least six months prior to diagnosis\n\nExclusion Criteria:\n\n1. Diagnosis of atypical parkinsonism\n2. Diagnosis of drug-induced parkinsonism\n3. Diagnosis of vascular parkinsonism\n4. Known allergy to pyridostigmine bromide or other study drug components\n5. Current or recent (within 90 days of enrollment) use of pyridostigmine for any reason\n6. History of any bowel surgery\n7. History of bladder or bowel obstruction\n8. Severe asthma or chronic obstructive pulmonary disease\n9. Meet exclusion criteria noted in the UK Parkinson's Disease Society Brain Bank Criteria, at the PI's discretion:\n\n   A.Exclusion of any of the following:\n   * Repeated strokes with stepwise progression of parkinsonian features\n   * Repeated head injury\n   * Definite encephalitis\n   * Oculogyric crises\n   * Neuroleptic treatment at onset of symptoms\n   * Greater than one affected relative\n   * Sustained remission\n   * Strictly unilateral features after 3 years\n   * Supranuclear gaze palsy\n   * Cerebellar signs\n   * Early severe autonomic involvement\n   * Early severe dementia\n   * Babinski sign\n   * Cerebral tumor or communicating hydrocephalus\n   * Negative response to large doses of levodopa\n   * 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure\n10. Significant abnormalities on laboratory analysis (complete blood count, comprehensive metabolic panel, thyroid stimulating hormone) conducted at the screening visit or within the three months prior if available for review\n11. Significant abnormalities on screening electrocardiogram conducted at the screening visit or within the three months prior if available for review\n12. Positive pregnancy test (if female of child-bearing age)\n13. Antibiotic use within two weeks prior to enrollment",{"count":560,"type":22},16,[128],"Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.",[155,28],"2026-02-20",{"date":566,"type":33},"2026-02-23",{"date":568,"type":33},"2022-08-10",{"date":570,"type":22},"2026-12-31",{"name":572,"class":40},"University of Vermont Medical Center",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":594},"100410350","usefulness-of-high-resolution-manometry-in-constipation-100410350","NCT04623359","Usefulness of High Resolution Manometry in Constipation","MANOCOHR","For patient\n\nInclusion Criteria:\n\n* Age between 18 and 65 years\n* chronic Constipation (\\> 6 months)\n* delayed colonic transit time \\> 100 h\n* normal colonoscopy\n* constipation refractory to at least 1 osmotic and 1 stimulant laxative according French guidelines on constipation ;\n* Affiliated to French national healthcare insurance\n\nExclusion Criteria:\n\n* Patient with constipation being either:\n\n  * With colonic transit time \\\u003C100h\n  * Distal (with radio-opaque markers stasis in the rectum)\n  * From organic origin\n  * Recent (\\\u003C6 mois)\n  * Relieved using osmotic or stimulant laxatives\n* Contra-indication to the use of high resolution manometry insertion\n\n  * Intestinal occlusion\n  * Coagulation disorders, including anti-coagulant treatments\n  * General anesthesia contra-indication\n  * colonoscopy contra-indication\n* failure to perform a colonoscopy in previous attempts\n* medication intake that may impair colorectal motility, including opioids\n* Evolutive inflammatory of neoplasia process\n* History of major digestive surgery (at exclusion of appendicectomy, cholecystectomy)\n* Presence of condition that may impact digestive motility, including diabetes mellitus and sclerodermia\n* Cardiologic disease that may represent a contraindication to vagal stimulation\n\nFor Healthy volunteers\n\nInclusion Criteria:\n\n* Age between 18 and 65 years\n* Affiliated to French national healthcare insurance\n\nExclusion Criteria:\n\n* Significant digestive evolutive disease\n* constipation with Kess score \\> 11\u002F39 and colonic transit time ≥ 60 h\n* Contra-indication to the use of high resolution manometry insertion\n\n  * Intestinal occlusion\n  * Cardiac disease\n  * Coagulation disorders, including anti-coagulant treatments\n  * General anesthesia contra-indication\n  * colonoscopy contra-indication\n* History of major digestive surgery (at exclusion of appendicectomy, cholecystectomy)\n* Presence of condition that may impact digestive motility, including diabetes mellitus and sclerodermia",{"count":104,"type":22},[25],"Constipation is a frequent symptom that is reported by more than 10% of the general population. In a few case, constipation is resistant to medical standard care, including osmotic and stimulant laxatives. The diagnosis of colonic inertia may be suspected in these patients although diagnostic criteria for colonic inertia may vary from one country to another. In France, the diagnosis of colonic inertia is based on manometric study of the colorectal contractile activity using manometric probe. Using conventional manometric catheters, severe alteration of the colorectal motility is found in a very small subset of patients, who may later benefit from surgery. The recent use of high resolution manometric probe allowed to map more precisely colorectal motility, but whether these new parameters are relevant remains to be assessed. The aim of this study is to assess the diagnostic performance of a new high resolution manometric probe by comparing healthy volunteers to patients suspected of colonic inertia.",[28],[585],"high resolution manometry","2026-02-05",{"date":588,"type":33},"2026-02-06",{"date":590,"type":33},"2023-01-25",{"date":138,"type":22},{"name":593,"class":40},"University Hospital, Rouen",3,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":603,"enrollmentInfo":604,"targetDuration":4,"studyType":292,"phases":4,"briefSummary":606,"conditions":607,"keywords":621,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":41},"100622820","soluble-and-osmotic-fibre-solos-diet-for-constipation-100622820","NCT07388589","Soluble and Osmotic Fibre (SOLOS) Diet for Constipation","The Soluble and Osmotic Fibre (SOLOS) Diet for Functional Bowel Disorders With Constipation","SOLOS","Inclusion Criteria:\n\n* Presented with symptoms of FC, IBS-C, or SIBO-C\n* Were aged 18 to 70 years old. (Research focus is on adult patients, excluding older adults and children)\n* Date of baseline (first) and follow-up appointments ranged from January 2021 to December 2025\n* Did not attend follow-up appointments (Data would be treated as \"intention to treat\" and data points were carried forward for conservative analysis).\n\nExclusion Criteria:\n\n* Had no history of constipation-related symptoms (Does not relate to research question's population or outcome)\n* Started treatment before January 2021\n* Were not due for follow-up before the end of December 2025\n* Symptom and stool data inadequately recorded","70 Years",{"count":605,"type":22},180,"This research aims to study the dual effectiveness of incorporating soluble fibre and osmotic carbohydrates (SOLOS), with or without restricting fructans and GOS, and present novel findings in managing GI symptoms in patients with functional bowel disorders with constipation. These findings may also support researchers and clinicians in shaping new dietary approaches in the management of general constipation symptoms.",[28,608,609,610,611,612,613,614,615,616,617,618,619,620],"Constipation - Functional","Constipation Chronic Idiopathic","Constipation Predominant Irritable Bowel Syndrome","Constipation, Signs and Symptoms, Digestive","Constipation-predominant IBS (IBS-C)","Constipation-predominant Irritable Bowel Syndrome","Constipation-predominant Irritable Bowel Syndrome (IBS-C)","Diet Therapy","Diet Modification","Diet, Food and Nutrition","Dietary and Nutritional Therapies","Dietary Fiber","Dietary Fibers",[28,622,623,624,625],"Functional constipation","Constipation-predominant irritable bowel syndrome (IBS-C)","Soluble fiber","osmotic sugar","2026-02-04",{"date":588,"type":33},{"date":629,"type":22},"2026-02-02",{"date":631,"type":22},"2027-03-01",{"name":633,"class":40},"Singapore Institute of Technology",{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":642,"enrollmentInfo":643,"targetDuration":4,"studyType":23,"phases":644,"briefSummary":645,"conditions":646,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":655,"locationsCount":41},"100622795","impact-of-weizmannia-bacillus-coagulans-jbi-yz63-on-gut-health-and-fecal-microbiome-changes-100622795","NCT07388264","Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","Examining the Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","WIZ","Inclusion Criteria Ages of 18 - 50 years Average daily bloating score \\>5 on question 3 of the Modified daily Abdominal, Gas, and Bloating Questionnaire and\u002For bloating for \\>5 days during the past 14 days Body mass index (BMI) 18.5 - 29.9 kg\u002Fm2 (Inclusive) (Individuals \\>29.9 kg\u002Fm2, but \\\u003C25% fat for men and \\\u003C30% fat for women will be accepted into the study. The cohort average of body mass index will not exceed 29.9 kg\u002Fm2) Weight stable for the past three months (defined as less than a 5% variation in body mass over this time) Determined to be healthy through completion of a health history questionnaire Subject agrees to maintain their existing dietary patterns throughout the study period and to report to study investigators any changes particularly as they relate to probiotic-containing or fermented foods Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.\n\nMinimum baseline physical activity level (defined as at least 30 minutes of moderate intensity exercise at least 4 days per week for the past 3 months) Subject is willing and able to comply with the study protocol. Study participant is not currently enrolled in another clinical trial that involves the administration of some investigative agent Subject has given voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals Has liver disease or some form of clinically diagnosed hepatic impairment Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL) Diagnosed with or is being treated for some form of thyroid disease Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS) History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n\nParticipant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) Participant has been treated for a gastrointestinal related disorder, complication, or disorder within the past 30 days Positive medical history for any neurological condition or neurological disease Diagnosed with or being treated for any endocrinological disorder or currently used any form of hormone replacement (prescribed\u002Fdoctor ordered or not) Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome Currently prescribed for the first time statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Currently prescribed for the first time hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Current antibiotic use or other prescription or over-the-counter medications that may impact study outcomes Have a known sensitivity or allergy to any of the study products Blood donation in past 60 days Current smoker (average of \\> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study Competitive athletes will be excluded History of alcohol or substance abuse in the 12 months prior to screening Current use of anabolic steroids (medically prescribed or otherwise) Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol Report taking a probiotic or other dietary supplement know to impact digestion or gut function in the past 30 days Recent history (\\\u003C3 months) of exercise training or weight loss (\\> 5%) Currently following a ketogenic or low carbohydrate diet within the past 30 days.\n\nWomen who are pregnant, planning to become pregnant, or lactating currently or within the past six months Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","50 Years",{"count":220,"type":22},[25],"This study will evaluate the effects of supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 on gastrointestinal health in healthy, physically active adults. The primary objective is to determine whether daily intake of this probiotic strain improves symptoms of constipation and related gastrointestinal function compared with placebo.\n\nApproximately 30 healthy men and women aged 18 to 50 years will be enrolled in a randomized, double-blind, placebo-controlled, crossover trial. Participants will complete two 4-week supplementation periods, one with Weizmannia (Bacillus) coagulans JBI-YZ6.3 and one with placebo, separated by a 4-week washout period. The total duration of participation will be approximately 13 to 14 weeks, including screening and testing visits.\n\nGastrointestinal symptoms will be assessed at baseline and after each supplementation period using validated questionnaires, with particular focus on the constipation domain of the Gastrointestinal Symptom Rating Scale (GSRS). Secondary outcomes will include additional gastrointestinal symptom domains and markers of perceived gut comfort and function.\n\nThis study is designed to determine whether supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 produces clinically meaningful improvements in gastrointestinal symptoms in physically active adults compared with placebo.",[647,28,648,649],"Gastrointestinal Symptoms","Gut Health","Gastrointestinal Function","2026-01-28",{"date":586,"type":33},{"date":653,"type":33},"2025-06-15",{"date":375,"type":22},{"name":656,"class":40},"Lindenwood University"]